Arbutus Biopharma Corporation reported $182M of revenue over the trailing twelve months, +1079% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $182M (to Q2 2026). Net income: $153M, trailing twelve months to Q2 2026. Free cash flow: −$40M, trailing twelve months to Q4 2025. Operating margin: −659%, trailing twelve months to Q2 2026.

ABUSArbutus Biopharma Corporation

Healthcare

$4.18-2.7% 1Y

$4.18

$3.6752 weeks$5.20

ABUS as reported

Arbutus Biopharma Corporation reported $182M of revenue over the trailing twelve months, +1079% on the year before. 9 reported series are charted on this page, each one as filed.

$182M

Revenue, trailing twelve months · to Q2 2026 · +1079% against the twelve months before

Net income: $153M
Net income · −382% year on year · trailing twelve months to Q2 2026
Free cash flow: −$40M
Free cash flow · trailing twelve months to Q4 2025
Operating margin: −659%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for ABUS, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$182M	+1079%	Q2 2026
Net income	$153M	−382%	Q2 2026
EPS	$0.79	−372%	Q2 2026
Operating margin	−659%	n/a	Q2 2026
Net margin	−558%	n/a	Q2 2026
ROE	5.6%	n/a	Q2 2026
ROA	8.8%	n/a	Q2 2026
ROIC	144%	n/a	Q2 2026
Free cash flow	−$40M	n/a	Q4 2025

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.